Results 81 to 90 of about 814,690 (301)
The Role of the Brain in the Pathogenesis and Physiology of Polycystic Ovary Syndrome (PCOS). [PDF]
, 2019 Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder, affecting at least 10% of women of reproductive age. PCOS is typically characterized by the presence of at least two of the three cardinal features of hyperandrogenemia (high ...
Coutinho, Eulalia A +1 more
core +1 more source
Molecular Oncology, EarlyView.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Ethical implications of preclinical studies
Регуляторные исследования и экспертиза лекарственных средств, 2018 Animal experiments are fundamental for the biomedical science. The development of new drugs is always associated with a large number of preclinical experiments in animals.
I. N. Tyurenkov +4 more
doaj
Prospects for non-immunological molecular therapeutics in melanoma [PDF]
, 2010 In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues.org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic and immunologic therapies,
Crown, John +4 more
core
Molecular Oncology, EarlyView.Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
Cancer Pathogenesis and TherapyMethionine restriction (MR) has shown significant promise in cancer therapy because it targets the unique methionine dependency of many tumors. However, despite extensive research on MR, a clear synthesis of preclinical findings and their translation ...
Nagaraju Bandaru +5 more
doaj +1 more source
EO9 (Apaziquone): from the clinic to the laboratory and back again [PDF]
, 2013 EO9 (Apaziquone) is a bioreductive drug that has a chequered history. It underwent clinical trial but failed to show activity in phase II clinical trials when administered i.v.
Aamdal +75 more
core +1 more source
Ibandronate: Pharmacology and preclinical studies
Bone, 2006 Over the past three decades, changes to the chemical structures of the bisphosphonates have resulted in progressive improvements in their antiresorptive potencies. Ibandronate is a potent, nitrogen-containing bisphosphonate that possesses a tertiary nitrogen group on its R2 side chain and a hydroxyl group on its R1 side chain, which together confer one
openaire +2 more sources
Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin
Molecular Oncology, EarlyView.Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon +4 more
wiley +1 more source
Vaccines with adjuvants. Preclinical studies
Биопрепараты: Профилактика, диагностика, лечение, 2018 The paper presents the data on safety and efficacy assessment of adjuvants and vaccines with adjuvants at the stages of development and preclinical studies based on international recommendations.
Zh. I. Avdeeva +10 more
doaj